Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

    Craig Venter became the first to successfully create synthetic life putting humankind at the threshold of the most important and exciting phase of biological research, one that will enable us to actually write the genetic code for designing new species to help us adapt and evolve for long-term survival. The science of synthetic genomics will have a profound impact on human existence, including chemical and energy generation, health, clean water and food production, environmental control, and possibly even our evolution. In "Life at the Speed of Light," Venter presents a fascinating and authoritative study of this emerging field from the inside detailing its origins, current challenges and controversies, and projected effects on our lives. This scientific frontier provides an opportunity to ponder anew the age-old question What is life? and examine what we really mean by playing God. " Life at the Speed of Light "is a landmark work, written by a visionary at the dawn of a new era of biological engineering."

    Top magazines including Fortune and Industry Week have repeatedly named it one of America's best companies to work for.In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen's climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.

    The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free.Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers.Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.

    We like to imagine that it’s based on evidence and the results of fair tests. In reality, those tests are often profoundly flawed. We like to imagine that doctors are familiar with the research literature surrounding a drug, when in reality much of the research is hidden from them by drug companies. We like to imagine that doctors are impartially educated, when in reality much of their education is funded by industry. We like to imagine that regulators let only effective drugs onto the market, when in reality they approve hopeless drugs, with data on side effects casually withheld from doctors and patients.All these problems have been protected from public scrutiny because they’re too complex to capture in a sound bite. But Dr. Ben Goldacre shows that the true scale of this murderous disaster fully reveals itself only when the details are untangled. He believes we should all be able to understand precisely how data manipulation works and how research misconduct on a global scale affects us. In his own words, “the tricks and distortions documented in these pages are beautiful, intricate, and fascinating in their details.” With Goldacre’s characteristic flair and a forensic attention to detail, Bad Pharma reveals a shockingly broken system and calls for something to be done. This is the pharmaceutical industry as it has never been seen before.

    Physician, researcher, and award-winning science writer, Siddhartha Mukherjee examines cancer with a cellular biologist’s precision, a historian’s perspective, and a biographer’s passion. The result is an astonishingly lucid and eloquent chronicle of a disease humans have lived with - and perished from - for more than five thousand years. The story of cancer is a story of human ingenuity, resilience, and perseverance, but also of hubris, paternalism, and misperception. Mukherjee recounts centuries of discoveries, setbacks, victories, and deaths, told through the eyes of his predecessors and peers, training their wits against an infinitely resourceful adversary that, just three decades ago, was thought to be easily vanquished in an all-out “war against cancer.” The book reads like a literary thriller with cancer as the protagonist. From the Persian Queen Atossa, whose Greek slave cut off her malignant breast, to the nineteenth-century recipients of primitive radiation and chemotherapy to Mukherjee’s own leukemia patient, Carla, The Emperor of All Maladies is about the people who have soldiered through fiercely demanding regimens in order to survive—and to increase our understanding of this iconic disease. Riveting, urgent, and surprising, The Emperor of All Maladies provides a fascinating glimpse into the future of cancer treatments. It is an illuminating book that provides hope and clarity to those seeking to demystify cancer.

    Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects.The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.

    Building a house would entail no more work than planting a seed in the ground. These scenarios may seem far-fetched, but pioneering geneticist George Church and science writer Ed Regis show that synthetic biology is bringing us ever closer to making such visions a reality. In Regenesis, Church and Regis explore the possibilities—and perils—of the emerging field of synthetic biology. Synthetic biology, in which living organisms are selectively altered by modifying substantial portions of their genomes, allows for the creation of entirely new species of organisms. Until now, nature has been the exclusive arbiter of life, death, and evolution; with synthetic biology, we now have the potential to write our own biological future. Indeed, as Church and Regis show, it even enables us to revisit crucial points in the evolution of life and, through synthetic biological techniques, choose different paths from those nature originally took. Such exploits will involve far more than just microbial tinkering. Full-blown genomic engineering will make possible incredible feats, from resurrecting woolly mammoths and other extinct organisms to creating mirror life forms with a molecular structure the opposite of our own. These technologies—far from the out-of-control nightmare depicted in science fiction—have the power to improve human and animal health, increase our intelligence, enhance our memory, and even extend our life span. A breathtaking look at the potential of this world-changing technology, Regenesis is nothing less than a guide to the future of life.

    On one side are parents, bombarded with stories about the dangers of vaccines, now wary of immunizing their sons and daughters. On the other side are doctors, scared to send kids out of their offices vulnerable to illnesses like whooping cough and measles--the diseases of their grandparents.How did anyone come to view vaccines with horror? The answer is rooted in one of the most powerful citizen activist movements in our nation's history. In Deadly Choices, infectious disease expert Paul Offit relates the shocking story of anti-vaccine America--its origins, leaders, influences, and impact. Offering strategies to keep us from returning to an era when children routinely died from infections, Deadly Choices is a vigorous and definitive rebuttal of the powerful anti-vaccine movement.

    Two scientists explore the potential of a revolutionary genetics technology capable of easily and affordably manipulating DNA in human embryos to prevent specific diseases, addressing key concerns about related ethical and societal repercussions.

    The doctor-patient relationship--the heart of medicine--is broken: doctors are too distracted and overwhelmed to truly connect with their patients, and medical errors and misdiagnoses abound. In Deep Medicine, leading physician Eric Topol reveals how artificial intelligence can help. AI has the potential to transform everything doctors do, from notetaking and medical scans to diagnosis and treatment, greatly cutting down the cost of medicine and reducing human mortality. By freeing physicians from the tasks that interfere with human connection, AI will create space for the real healing that takes place between a doctor who can listen and a patient who needs to be heard.Innovative, provocative, and hopeful, Deep Medicine shows us how the awesome power of AI can make medicine better, for all the humans involved.

    But by itself, DNA is just an inert blueprint for life. It is the ribosome--an enormous molecular machine made up of a million atoms--that makes DNA come to life, turning our genetic code into proteins and therefore into us. Gene Machine is an insider account of the race for the structure of the ribosome, a fundamental discovery that both advances our knowledge of all life and could lead to the development of better antibiotics against life-threatening diseases. But this is also a human story of Ramakrishnan's unlikely journey, from his first fumbling experiments in a biology lab to being the dark horse in a fierce competition with some of the world's best scientists. In the end, Gene Machine is a frank insider's account of the pursuit of high-stakes science.

    That scientist, David Hungerford, had no way of knowing that he had stumbled upon the starting point of modern cancer research—the Philadelphia chromosome. This book charts not only that landmark discovery, but also—for the first time, all in one place—the full sequence of scientific and medical discoveries that brought about the first-ever successful treatment of a lethal cancer at the genetic level.The significance of this mutant chromosome would take more than three decades to unravel; in 1990, it was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. This dramatic discovery launched a race involving doctors and researchers around the world, who recognized that in principle it might be possible to target CML at its genetic source.Science journalist Jessica Wapner brings extensive original reporting to this book, including interviews with more than thirty-five people with a direct role in this story. Wapner reconstructs more than forty years of crucial breakthroughs, clearly explains the science behind them, and pays tribute to the dozens of researchers, doctors, and patients whose curiosity and determination restored the promise of a future to the more than 70,000 people worldwide who are diagnosed with CML each year. Chief among them is researcher and oncologist Dr. Brian Druker, whose dedication to his patients fueled his quest to do everything within his power to save them.The Philadelphia Chromosome helps us to fully understand and appreciate just how pathbreaking, hard-won, and consequential are the achievements it recounts—and to understand the principles behind much of today’s most important cancer research, as doctors and scientists race to uncover and treat the genetic roots of a wide range of cancers.

    In this gripping account, David Quammen takes the reader along on this astonishing quest to learn how, where from, and why these diseases emerge and asks the terrifying question: What might the next big one be?